Anti-C19 Antikörper mit reduzierter Immunogenizität

Patent europeic · EP2270050 · En vigur

Inscripziun en il register

Numer da publicaziun
EP2270050
Numer da la dumonda
EP10008056
Gener
Patent europeic cun effect per la Svizra ed il Liechtenstein
Status
En vigur
Scrittira da patent
Concedì
Annunzià
21-12-2006
Publitgà
05-01-2011
Concedì
05-06-2013
La protecziun finescha il pli tard
20-12-2026
Proxima taxa annuala scadenta
31-12-2026
Classas IPC
C07K 16/28 (2006.01)
C12N 15/13 (2006.01)
C12N 15/85 (2006.01)
C12N 15/10 (2006.01)
A61K 39/395 (2006.01)
A61P 35/00 (2006.01)
A61P 37/04 (2006.01)
A61K 31/00 (2006.01)
Prioritad
US 755609 P 30.12.2005
Derivà da
EP06829801
Lingua da l’annunzia
englais
Funtauna
Swissreg

Istorgia

Quai che l’Institut federal da la proprietad intellectuala ha publitgà davart quest titel, il pli nov l’emprim.

  1. 01-01-2026

    Midada

    Published in Swissreg on 01.01.2026

  2. 01-01-2025

    Midada

    Published in Swissreg on 01.01.2025

  3. 09-01-2024

    Midada

    Published in Swissreg on 09.01.2024

  4. 04-01-2023

    Midada

    Published in Swissreg on 04.01.2023

  5. 21-10-2020

    Transferì

    Owner
    Merck Patent GmbH, Frankfurter Strasse 250, 64293 Darmstadt, Germany → Cancer Research Technology Limited, Angel Building, 407 St. John Street, London EC1V 4AD, United Kingdom

    Published in Swissreg on 21.10.2020

  6. 05-06-2013

    Concedì

    Published in Swissreg on 05.06.2013

Partidas

Possessur

CANCER RESEARCH TECHNOLOGY LIMITED

Cancer Research Technology Limited

Angel Building 407 St. John Street, London EC1V 4AD, GB

Inventur

Super, Michael

Lexington, MA 02421, US

Davis, Jonathan H.

Auburndale, MA 02466, US

Stein, Pascal André

Boston, MA 02120, US

Il register numna mintga partida cun num ed adressa. In possessur u in represchentant vegn collià cun in’organisaziun, sch’exact ina unitad giuridica dal register da commerzi porta ses num; la via d’ina partida betg enconuschida uschia na vegn betg mussada qua.